Key Market Indicators
Iceland is set to become a major force in the global blood and blood forming organs medicine sales and anemia prevalence market. Sales of blood and blood forming organs medicine in the country are projected to reach $26.1 million by 2026, a 2.6% year-on-year increase since 2021. Since 1985, Iceland's market has grown 6.9% year on year, coming in at number 30 in 2021. Germany, Italy and South Korea respectively ranked second, third and fourth. Hospital discharges due to anemia prevalence in Iceland are estimated to reach 181 by 2026, a decrease of 2.1% year on year since 2021. Demand for anemia treatment has decreased by 5.6% year on year since 2005. The country ranked 32nd in 2021, with Luxembourg coming in first with 206 hospital discharges. Germany, the United Kingdom and Poland were the top three.
